Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Fentanyl
PecFent
Routinely available
SMC (663/10)
17/08/2011
Indication
Management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. SMC restriction: restricted to use in patients unsuitable for short-acting oral opioids, as an alternative to other fentanyl preparations.
Therapeutic Area
Central nervous system
Status Description
Routinely available
Formulation
100microgram/dose and 400microgram/dose nasal spray solution
Comments
August 2011 - Added to the Additional List, for Specialist Initiation.